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The Heymann nephritis (HN) models of rat membranous
nephropathy are extraordinarily valuable tools to investigate
the immunopathology of glomerular subepithelial immune de-
posit formation and the mechanism by which such deposits
injure glomeruli. The immunopathology of HN is reviewed by
Brentjens and Andres in this volume [1]. In this review we will
largely confine ourselves to a discussion of the mediators,
mechanisms and pathophysiological consequences of renal in-
jury in rat membranous nephropathy.
The primary manifestation of glomerular injury in HN is
proteinuria; however there are also subtle, but not trivial,
changes in glomerular hemodynamics and tubular function, and
alterations in renal hormone production. The alterations in
glomerular permselectivity that lead to proteinuria closely
resemble the defect in human membranous nephropathy, and
the rat model has been used to study mechanisms of renal
sodium retention, edema formation and metabolic abnormali-
ties in nephrotic syndrome. Investigators have also used the
RN models to study the impact of systemic hypertension on
pre-existing glomerular disease, in terms of both altered gb-
merular function and progressive renal injury.
Mostly, the mechanisms and effects of glomerular injury in
rat membranous nephropathy have been investigated in the
standard active and passive (PJ-IN) models of HN; however,
both models have also been extensively modified to elucidate
specific mechanisms or mediators. Such modifications, which
include the use of the isolated perfused kidney, renal transplan-
tation, partial renal ablation and, more recently, cell and tissue
culture, will be discussed in context later in this review.
Active RN is induced by immunizing susceptible strains of
rats (such as, Lewis, Fisher) with certain fractions of homolo-
gous or heterologous proximal tubular brush border and is
characterized by granular glomerular capillary wall deposits of
rat IgG and subepithelial electron-dense deposits after three to
four weeks. Proteinuria develops in 30 to 80% of rats within
eight to ten weeks of immunization. PHN is induced by a single
intravenous injection of heterologous anti-brush border antise-
rum (anti-Fx1A) that produces heterologous IgG deposits which
accumulate in gbomeruli over hours and days. When an appro-
pritte complement-fixing antiserum is used, proteinuria occurs
in almost all animals within five days [2, 31. This "heterologous
phase" is then followed by an autologous phase during which
rat IgG antibodies with specificity for the heterologous glomer-
ular-bound IgG are deposited and induce a further increase in
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proteinuria. RN more closely resembles human membranous
nephropathy in its slow evolution than does PHN and it is truly
an autoimmune disease. In those HN rats that become protein-
uric, urine protein excretion and glomerular dysfunction tend to
be more severe than in PHN; however, the variability between
animals and the duration of onset make it a less suitable model
than PHN for studying the mediators of injury.
Mediation of injury in PHN
Role of complement
There is now considerable evidence that implicates the C5b-9
membrane attack complex (MAC) in immunological injury to
the glomerulus [reviewed in 4, 5], and most derives from the
study of the PHN model of experimental membranous nephrop-
athy in which the glomerular visceral epithelial cell (GEC)
appears to be the primary target of injury. The first clue was
provided by the observation that urine protein excretion in
PHN is mediated by complement but is leukocyte-independent
[6]. A single intravenous injection of anti-Fx1A results in
binding of antibody to intrinsic GEC antigens and formation of
subepithelial immune deposits in situ [7, 8]. Activation of the
complement cascade by the subepithelial immune complexes
leads to proteinuria four to five days after the administration of
antibody (Table 1). Granular deposits of rat C3 are present in
identical distribution to heterobogous IgG, but without detect-
able leukocyte infiltration by either light or electron micros-
copy. Decomplementation of rats with cobra venom factor,
before administration of antibody, does not affect glomerular
antibody deposition, but abrogates the proteinuria (Table 1). In
contrast, administration of anti-neutrophil serum prior to anti-
FxlA has no effect on protein excretion (Table 2).
Injury is mediated by similar mechanisms in the autologous
phase of PHN [9]. Kidneys from rats passively immunized with
a subnephritogenic dose of non-complement-fixing 72 sheep
anti-Fx 1 A IgG ("planted" antigen) were transplanted into
recipient rats that were either actively pre-immunized with
sheep IgG or passively immunized with complement-fixing
anti-sheep IgG, and both groups developed proteinuria. Pro-
teinuria did not develop when rats, either actively or passively
immunized, were decomplemented with cobra venom factor
prior to transplantation. Neutrophil depletion of passively im-
munized animals did not inhibit the development of proteinuria.
In PHN, complement-depletion appears to be ineffective at
abolishing proteinuria once it has already been established.
Administration of cobra venom factor to rats with PHN during
the naturally-occurring autobogous phase of the disease (>8
days after injection of heterologous anti-Fx 1A) does not dimin-
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Group
Serum C3, day 5
% base line
Urine protein, day 4—5
mg/24 hr
Saline 133 121 (6) 70 15 (16)
CVF 6±4(13) 4±1(16)
Table 2. Unne protein excretion in rats with PHN treated with anti-
neutrophil globulin or nonimmune globulin
Group
Neutrophil count Urine protein, day 3—4
cells/m,n3 mg/24 hr
Nonimmune
Anti-neutrophil
Number studied is in parentheses. From [7J.
a Range of daily neutrophil counts
b Mean SEM
1100—5000 (6) 25 10 (6)b
0—200 (5) 34 10 (5)
ish protein excretion [61. The reason for this is not established,
but the findings suggest that additional mechanisms may be
involved in the maintenance of glomerular injury after the initial
complement-dependent insult.
These studies exclude a role for the chemotactic effects of
complement, and when taken in conjunction with the findings in
a rabbit model of membranous nephropathy [101, suggest that
injury in PHN is mediated by the terminal C components that
form the C5b-9 membrane attack complex (MAC). Activation
of the terminal complement pathway [reviewed in 111 follows
cleavage of C5 by the C5 convertase and leads to the formation
of the C5b6 complex which remains associated with the C5
convertase and is able to bind C7. The C5b-7 complex acquires
hydrophobic phospholipid-binding domains after binding C7
and can insert into a cell membrane but without deleterious
effects on membrane integrity. It can, however, bind C8 and the
resulting complex induces membrane damage in a process
accelerated by the subsequent binding of C9. Thus, C8 is the
component of the MAC which is essential for membranolysis.
Depletion of C8 is difficult to achieve experimentally in vivo,
and there are no C8-deficient strains of rats. Therefore, a
cell-free isolated perfused kidney model was used to obtain
definitive evidence for the pathogenic role of MAC in PHN [121.
As in the passive-autologous model in vivo, rats were injected
with a subnephritogenic dose of the non-complement-fixing y2
subclass of sheep anti-Fx1A IgG prior to kidney perfusion; this
was done to provide a "planted" antigen. Kidneys were then
removed and perfused in vitro with complement-fixing anti-
sheep IgG together with various human plasmas as a source of
complement. Perfusions with complement-replete normal
plasma resulted in a marked increase in proteinuria (Table 3). In
contrast, protein excretion remained at control values when
kidneys were perfused C8-deficient plasma (Table 3) from an
individual with a congenitally dysfunctional C8 molecule [13].
Reconstitution of the C8-deficient plasma with normal C8
restored proteinuria to the level seen with normal plasma.
Glomerular antibody deposition was not affected by the ab-
sence of C8 [12]. Similar observations have also been made
using a heterologous-phase model of PHN in the isolated
perfused rat kidney [14]. Perfusion of kidneys containing com-
Group
CH50
% normal
Urine protein, 110 mm
g/min
With antigen
Normal plasma 50 4269 l208' (8)
Heat-inactivated plasma 0 102 57 (6)
C8-deficient plasma 0 236 62 (6)
Without antigen
Normal plasma 50 299 122 (6)
plement-fixing yl anti-Fx1A IgG resulted in increased protein-
uria when perfused simultaneously with complement-replete
plasma, but not with C8-deficient human plasma or C6-deficient
rabbit serum. Whereas the combined use of the C8- and
C6-deficient reagents, whether simultaneously or in sequence,
simulated the effect of normal plasma. It is reasonable to
conclude that injury in PHN is mediated by the MAC as the
only known function of C8 is its essential role in complement-
mediated membrane injury.
This conclusion is supported by a study in which rats were
depleted of C6 in vivo by injection of an IgG fraction or F(ab')2
fragments of an antibody against rat C6 which reduced serum
C6 hemolytic activity to <5% of normal [15]. These rats
developed subepithelial immune deposits in amounts equal to
those in complement-replete rats after administration of anti-
Fx1A but proteinuria develored only in rats with an intact
terminal complement pathway.
Formation of the MAC results in the development of MAC
"neoantigens" [11]; antigenic determinants that are found on
the assembled complex of C5b-9 but not on the individual
complement molecules. Antibodies that recognize only the
neoantigenic determinants have been used to demonstrate, by
direct immunofluorescence [16] and by immunoelectron micros-
copy [17], the MAC complex in glomeruli of rats with PHN.
Moreover, the presence of the MAC correlated with comple-
ment-mediated proteinuria [16]. In these models of PHN,
glomerular injury develops relatively acutely, enabling the
investigators to define a functional role for terminal comple-
ment components, either in vivo or in vitro. It is more difficult
to show that the MAC has a functional role in active HN
because long-term complement depletion is not technically
feasible. Nevertheless, indirect evidence suggests that protein-
uria is also complement-mediated in active HN. Immunization
of Lewis rats, or other susceptible strains, with Fx1A, results in
the development of subepithelial immune deposits in all rats
after six weeks [181. Of these, about 60% demonstrate glomer-
ular C3 deposition by immunofluorescence microscopy and are
proteinuric. The remainder do not have C3 deposits and excrete
normal levels of protein but if given a booster injection of Fx IA,
roughly 60% will develop glomerular deposits of C3 and pro-
teinuria. Terminal complement components and MAC neoanti-
gens can be identified in the glomeruli of rats with HN, and are
distributed in a peripheral granular pattern resembling that of
IgG and C3 [19]. Thus, the close association of proteinuria with
glomerular complement deposits in the absence of inflammatory
Table 1. Urine protein excretion in rats with PHN treated with
cobra venom factor (CVF) or saline
Table 3. Urine protein excretion in isolated rat kidneys with or
without subepithelial antigen, perfused with antibody and plasmaa
Values are mean SEM; number studied is in parentheses. From [7].
a Human plasma: 50% vol/vol in buffer containing bovine albumin;
b Mean 5EM; number studied is in parentheses. From [131.
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Fig. 1. Glomerular epithelial cell lesions induced by antibody and complement in the isolated perfused kidney model of autologous-phase PHN.
(A) Kidney containing y2 sheep anti-Fx IA, perfused with complement-fixing anti-sheep IgG and heat-inactivated plasma. Electron-dense deposits
(arrows) are present in the subepithelial space. Epithelial morphology appears normal. Notice preservation of the diaphragms in epithelial slits (x
35,000). Similar morphology was observed in antigen-containing kidneys perfused with antibody and C8-deficient plasma. (B) Kidney containing
y2 sheep anti-FX1A, perfused with anti-sheep IgG and complement-replete plasma. Glomerular capillary loop shows striking epithelial cell
abnormalities, with effacement of foot processes, microvillous transformation of the plasma membrane and vacuolization. Electron-dense deposits
(arrows) are present on the epithelial side of the GBM. Retraction of epithelium, disruption of filtration slit diaphragms and formation of small
membrane vesicles (arrowheads) are seen in the vicinity of electron-dense deposits in the lamina rara externa (X 35,000). US, urinary space; CL,
capillary lumen. Electron micrographs were kindly provided by Dr. Helmut Rennke, Brigham and Women's Hospital, Boston, MA, USA.
cells suggests that glomerular injury in HN is dependent on the
formation of the MAC.
Target of injury
The studies reviewed in the previous section provide strong
evidence that the MAC is present and active in inducing
glomerular capillary wall injury in PHN. The late stages of both
PHN and active HN are characterized by distortion and thick-
ening of the glomerular basement membrane (GBM) around
subepithelial immune deposits but it is not known whether the
GBM is the primary site of damage. Moreover, in early PHN
proteinuria occurs before ultrastructural changes in the GBM
are apparent [2]. This does not preclude the possibility that
alteration of the biochemical composition of the GBM might
change its charge-selective and/or size-selective filtration prop-
erties. On the other hand, there are several reasons for believ-
ing that visceral glomerular epithelial cells (GEC) are the initial
target of the antibody-directed, complement-mediated injury
that is responsible for proteinuria. Effacement and displace-
ment of epithelial cell foot processes, and microvillous trans-
formation are found in PFIN, and are accompanied by GEC
dysfunction as demonstrated by the impaired clearance of
protamine-heparin aggregates [201. These GEC changes are not
unique to PHN, and occur in other proteinuric disorders
associated with epithelial injury, including aminonucleoside
nephrosis [211. More direct evidence for GEC injury in PHN
has been obtained from the isolated perfused kidney model [12].
In these experiments, kidneys perfused in vitro with comple-
ment-fixing antibodies and heat-inactivated or C8-deficient hu-
man plasmas contained glomerular subepithelial electron-dense
deposits but had normal GEC morphology (Fig. 1A). In con-
trast, kidneys perfused with the same antibody in the presence
of complement developed severe GEC injury in the vicinity of
subepithelial immune deposits (Fig. 1B); the changes included
C-
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extensive effacement of foot processes and villous transforma-
tion, and microvesiculation of the plasma membranes, and
vacuolization and degeneration of some of the epithelial cells.
In some capillary ioops the epithelium detached to leave the
GBM denuded (Fig. 1B). In the majority of loops, however, the
GEC were abnormal but apparently viable. Such changes have
not been demonstrated in isolated perfused kidneys made
proteinuric by other methods which are complement-indepen-
dent [22, 23]. This indicates that they are unlikely to be
nonspecific effects of proteinuria but are likely to be the result
of CSb-9 insertion into the plasma membranes. The severity of
GEC injury seen in the perfused kidney model is probably
facilitated by delivery of complement to the subepithelial space
due to the intrinsic proteinuric nature of the model and by the
use of heterologous complement components [14]. Neverthe-
less, these studies show conclusively that sublethal GEC injury
can occur when MAC is assembled in the subepithelial space by
complement-fixing antibodies. Moreover, the prompt onset of
proteinuria coincident with the appearance of GEC injury,
makes it unlikely that alterations in GBM composition are the
cause of proteinuria.
Direct evidence of localization of the MAC in PHN has been
provided by a recent immunoelectron microscopic study [17].
Using a monoclonal antibody to rat C5b-9 neoantigens, Ker-
jaschki et al showed that C5b-9 was localized in subepithelial
immune deposits at the GBM-GEC interface, as well as in GEC
multivesicular bodies, and was visible being exocytosed from
GEC into the urinary space. The authors concluded that the
MAC was assembled on the GEC membrane near the site of
immune deposits, was selectively transported intracellularly,
and was then extruded into the urinary space.
Schuize et a! [24] have obtained additional evidence for C5b-9
assembly on the epithelial aspect of the glomerular capillary
wall. Using an enzyme-linked immunoabsorbent assay for
MAC neoantigens, they showed that the C5b-9 complex was
shed into the urine of rats with PHN, but was confined to the
circulation of rats made proteinuric with aminonucleoside of
puromycin and infused with zymosan-activated serum, and of
proteinuric rats in which immune deposits were formed on the
endothelial aspect of the capillary wall. Thus, it was demon-
strated that the MAC is too large to traverse the GBM despite
heavy proteinuria, and that urinary excretion of the MAC may
be a marker of complement-mediated GEC injury.
Secondary mediators of proteinuria
Nucleated cells are generally more resistant to complement
attack than erythrocytes, and require multiple "hits" by the
MAC for lysis to occur [25]. Furthermore, in nucleated cells,
"sublytic" amounts of the MAC can alter plasma membrane
integrity without causing cytolysis, and can activate cells to
produce various soluble mediators, some of which have been
implicated in disorders of glomerular permselectivity. Among
these, the role of eicosanoids has been examined most closely,
both in cultured GEC [26] and in PHN. Glomerular thrombox-
ane production is increased in proteinuric rats with PHN [27,
28] and this increase is complement-dependent [27]. Cyclooxy-
genase inhibition with indomethacin reduces proteinuria by
—60% in active HN [29] and by 74% in the autologous phase of
PHN [28]; in this latter study, there was a quantitatively similar
decrease in urinary thromboxane excretion. The glomerular
filtration rate was not substantially altered in either study. In
the isolated perfused rat kidney model of PHN, inhibition of
thromboxane synthetase with OKY-046, in doses sufficient to
suppress renal thromboxane production, reduced complement-
dependent proteinuria by —75% without altering glomerular
filtration rate or renal vascular resistance [301. In contrast, in
vivo treatment of PHN rats with the thromboxane synthetase
inhibitor UK38485 inhibited glomerular thromboxane produc-
tion by —80% in the heterologous phase [27] and urinary
thromboxane excretion by about 50% in the autologous phase
[28], but in neither case did it reduce proteinuria. Thus, it
appears that complement-mediated GEC injury can induce
endogenous glomerular cells to increase their production of
eicosanoids (particularly thromboxane A2), but that the patho-
physiological consequences of this phenomenon are, as yet,
incompletely understood. Further studies will be required to
determine whether augmented glomerular eicosanoid synthesis
in PHN is incidental to cellular injury and the functional
derangements, or not.
The administration of scavengers of reactive oxygen species
to rats with PHN has suggested a role for reactive oxygen
species in the pathogenesis of glomerular injury. By analogy to
observations in cultured mesangial cells [31], complement-
mediated injury of GEC in PHN could be associated with the
production of reactive oxygen species, and thus be involved in
the mediation of proteinuria. This has been investigated by
administration of dimethylsulfoxide (DMSO), a scavenger of
the hydroxyl radical, shortly after injection of heterologous
anti-Fx1A, or later, when glomerular injury was already estab-
lished. It resulted in a —60% reduction in proteinuria during the
autologous phase [32, 33]. In these studies, immunofluores-
cence staining for glomerular C3 suggested that less C3 was
deposited in glomeruli of rats that were treated with DMSO.
Therefore, while DMSO may have reduced proteinuria by
inhibiting production of the hydroxyl radical, the authors sug-
gested that DMSO may have acted by reducing glomerular
complement deposition. Recently, Shah [341 demonstrated that
dimethylthiourea, another scavenger of the hydroxyl radical,
reduced heterologous phase proteinuria in PHN by >60%. In
these experiments, quantitative studies of radiolabelled anti-
FxIA binding demonstrated that there was no reduction in
antibody deposition in dimethylthiourea-treated rats compared
to untreated controls, and immunofluorescence microscopy
suggested that there was no difference in C3 deposition between
the two groups. A second hydroxyl scavenger, sodium ben-
zoate, also produced a large reduction in proteinuria as did the
iron-chelating agent deferoxamine. This suggests that iron
participates in the generation of hydroxyl radicals through the
Haber-Weiss reaction. In contrast, superoxide dismutase, a
superoxide scavenger, and catalase, a hydrogen peroxide scav-
enger do not affect proteinuria. While these latter observations
suggest that the superoxide radical and hydrogen peroxide are
not involved in the pathogenesis of proteinuria in PHN, it
should be noted that superoxide dismutase and catalase are
large molecules that may not be able to effectively permeate
through the GBM to the GEC, the site of injury and likely site
of oxygen radical generation. Nevertheless, these results impli-
cate intracellularly generated hydroxyl radicals in the develop-
ment of proteinuria in PHN. The mechanism by which the MAC
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produces reactive oxygen species in GEC remains to be eluci-
dated.
Pathophysiology of Heymann nephritis
Proteinuria, the principal functional abnormality in HN and
PHN could arise in two possible ways. First, an increase in
macromolecular flux across the glomerular capillary wall could
occur purely on the basis of glomerular hemodynamic alter-
ations. Second, the permselective properties of the filtration
barrier could be altered by structural or compositional changes
in the capillary wall.
Functional and morphological changes documented in the
isolated perfused rat kidney model of experimental MN [12]
point to a structural defect in the filtration barrier, and suggest
that this defect is sufficient to cause proteinuria; however,
additional data indicates that the magnitude of the defect is
influenced by hemodynamic factors. Micropuncture studies in
Munich Wistar rats have shown that glomerular function in
PHN is characterized by marked proteinuria, elevated trans-
capillary hydraulic pressure difference, and depressed ultrafil-
tration coefficient; the net effect reduces single nephron glomer-
ular filtration rate (SNGFR) [35—38]. In addition, using dextran
clearance techniques, Yoshioka et al demonstrated that frac-
tional clearance of low molecular weight uncharged dextrans
(radius of 28 to 40A) is similar in PHN and control rats, but that
of large dextrans (radius >40A) is elevated in PUN [38]. A
theoretical model of macromolecule transfer that depicts the
glomerular capillary wall as a size-selective isoporous mem-
brane with a minor nonselective "shunt" pathway [39] revealed
that the calculated mean pore radius is similar in PHN and
control rats, but the fraction of filtrate permeating the shunt
pathway in PHN is greater than in controls [38]. Acute blockade
of angiotensin II in PHN lowers glomerular capillary pressure
(and SNGFR) but has no effect on proteinuria (or ultrafiltration
coefficient) [40]. In contrast, intra-aortic infusion of angiotensin
II further elevates the transcapillary hydrostatic pressure dif-
ference and aggravates the fractional clearance of large dex-
trans, protein excretion, and fraction of filtrate permeating the
shunt pathway [38]. Normalizing the transcapillary pressure
difference of proteinuric PHN rats by intra-aortic infusion of
acetylcholine brings about a partial parallel decline in the
fractional clearance of large dextrans together with a similar
reduction in urine protein excretion and the fraction of filtrate
permeating the shunt pathway [38]. These results indicate that
the size-selective defect in PHN is aggravated by glomerular
hypertension and that the sieving abnormality is alleviated, but
not abolished, by lowering glomerular capillary pressure. Par-
enthetically, the macromolecular clearance data and sieving
defect in PHN are similar to those described in human MN by
Shemesh et al [413.
It is still not known how nonlytic, complement-mediated
GEC injury contributes to proteinuria, and one can only spec-
ulate on possible mechanisms. These include GEC shape alter-
ations that might distort the GBM and lead to a loss of GBM
permselectivity, or displacement and disruption of filtration
slit-diaphragms causing defects in the epithelial barrier. The
GEC is also partly responsible for the synthesis and mainte-
nance of the GBM by synthesizing matrix components includ-
ing type IV collagen, laminin and proteoglycans. Although
disordered matrix synthesis and/or degradation may be respon-
sible for long-term alterations in glomerular permeability and
GBM thickening characteristic of advanced experimental [42]
and human MN, it probably does not account for the rapid
onset of complement-mediated proteinuria seen in PHN.
The role of complement in the hemodynamic alterations in
PHN has not been fully elucidated. Recent data suggest that
complement may be responsible for the elevated transcapillary
pressure gradient and reduced ultrafiltration coefficient in PHN
[37]. This effect could be due to the direct action of C5a [43] or
secondary to vasoactive cicosanoids or other inflammatory
mediators released from complement-injured glomerular cells
[26—34].
The pathophysiology of glomerular and tubular function have
also been studied in HN. In early HN, before the onset of
proteinuria, GFR, SNGFR and renal plasma flow (RPF) are
normal; however, after the onset of proteinuria, whole kidney
GFR and RPF are reduced by about 40%, and proximal tubular
dysfunction (including reduced glucose and fluid reabsorption
and impaired organic anion secretion) is observed [44]. At this
stage, SNGFR is uniformly depressed and the tubular disorders
coincide with the filtration and binding of anti-brush border
antibodies to proximal tubular cells together with morphologi-
cal evidence of tubular injury (Brentjens, this volume, 1). Later
in the course of HN, substantial heterogeneity of nephron
function develops [35, 45]. Whole kidney GFR is persistently
reduced by 30 to 40% but SNGFR is found to vary widely
between nephrons, apparently due to variable closure of gb-
merular capillary loops [35, 45]. Despite this heterogeneity,
glomerulotubular balance is well maintained and the absolute
proximal tubular reabsorption of fluid and SNGFR are directly
correlated in individual nephrons [35]. The variability of neph-
ron function in HN has been ascribed to nonuniform distribu-
tion of IgG and C3 in different glomeruli [35, 45] but not all
investigators agree [44].
The superimposed effect of pre-existing hypertension on
proteinuria, blood pressure, renal function and renal morphol-
ogy in HN has been studied in spontaneously hypertensive rats
(SHR) [46, 47] and in rats made hypertensive with oral desoxy-
corticosterone acetate and 1% saline (so-called DOCA-salt
hypertension) [48—50]. Blood pressure is usually normal in rats
with HN and PHN [46, 49, 50]. DOCA-salt hypertension
accelerates the onset and exacerbates the severity of protein-
uria, reduces survival and causes glomerular sclerosis and
tubulointerstitial and vascular damage in HN [49]. Similar
effects have been observed in the autologous phase of PHN,
associated with accentuated thickening of the GBM [501.
DOCA-salt hypertension is also more severe in rats with HN
[48]. On the other hand, HN only modestly aggravates hyper-
tension in SHR [46, 48], but there is a marked increase in
proteinuria and profound effects on renal morphology; these
include accelerated focal glomerular sclerosis and interstitial
fibrosis, and proliferative and necrotizing arteriolitis reminis-
cent of malignant hypertension [47]. These findings in SHR
have interesting pathophysiological implications. They suggest
that, in contrast to the situation in non-nephritic SHR, the high
systemic blood pressure is transmitted to some hyperperfused
glomeruli in SHR with HN [35, 451. This would be expected to
exacerbate the defect in glomerular permselectivity [38] and
might lead to focal glomerular sclerosis [51]. The necrotizing
vascular lesions in HN-SHR are not seen in non-nephritic SHR
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and have been attributed to intravascular thrombosis and hy-
percoagulability [47].
Heymann nephritis as a model of nephrotic syndrome
During the course of HN, affected animals develop biochem-
ical abnormalities similar to those in human nephrotic syn-
drome: namely, hypoalbuminemia with decreased plasma col-
bid oncotic pressure, hyperlipidemia, and elevated plasma
concentrations of fibrinogen and depressed plasma concentra-
tions of antithrombin III [52, 53]. Despite the reduction in
plasma colloid oncotic pressure and alterations in coagulation
factors, edema and thromboembolic phenomena are unusual in
HN [53]. The lack of edema in HN is reflected by a normal
relationship between the plasma volume and extravascular
sodium space [53]. However, when extracellular volume is
expanded by inducing renal insufficiency with 7/8 nephrectomy,
rats with HN develop edema and ascites [53]. This may be
explained by the finding that rats with HN have a reduced
ability to excrete a salt load during plasma volume expansion,
an effect attributed to increased distal tubular reabsorption of
sodium [54]. Kaysen, Kirkpatrick and Couser [55] have studied
the effect of dietary protein on albumin metabolism in PHN.
Regardless of diet, all animals had progressively declining
serum albumin levels for 10 days following anti-Fx1A injection,
at which time steady state hypoalbuminemia was reached
despite continuing heavy proteinuria. In PHN rats fed a normal
or high protein diet, this steady state was due to a combination
of increased synthesis and decreased catabolism of albumin.
Serum albumin was maintained constant in rats fed a low
protein diet because of increased albumin synthesis.
Progressive PHN
Following the acute severe proteinuria of PHN, there is a
period of stable, low-grade proteinuria lasting for 60 to 150 days
[56]. After this so-called latent phase, proteinuria increases
progressively and is associated with decreasing creatinine clear-
ance, hypertension and eventually death. The morphological
features of the chronic phase include thickened GBM with
intramembranous electron dense deposits, and heterobogous
and autologous IgG deposits by immunofluorescence [56].
Progressive PHN with severe proteinuria after 16 weeks and
circulating autoantibodies to brush border has been induced in
rats already made proteinuric by pre-immunization with bovine
serum albumin to induce serum sickness [57] or by injection of
anti-GBM antiserum [58]. Progressive injury is also affected by
uninephrectomy [42]; again proteinuria does not diminish after
the acute phase of PHN, but increases progressively up to 29
weeks following anti-FxlA injection. These animals developed
mesangial sclerosis associated with deposition of type IV col-
lagen and the MAC in sclerotic areas; they also develop
glomerular crescents and interstitial fibrosis [42]. These results
together with the effects of hypertension [46, 48, 50] emphasize
the potential role of hemodynamic factors in determining the
outcome of immunologic renal disease.
Complement induced injury of cultured glomerular epithelial
cells
Improved techniques for stable GEC culture [59] have pro-
vided the opportunity to test whether nephritogenic antibodies,
such as anti-Fx1A are capable of inducing complement-depen-
dent cytotoxicity in vitro and are particularly suitable to inves-
tigate the sublytic cytotoxic effects of complement at a cellular
level.
Anti-Fx1A and anti-gp 330 bind directly to the plasma mem-
brane of cultured rat GEC [60, 61], and so we [62] and others
[63], have assessed the ability of nephritogenic anti-Fx1A to
induce cellular damage of primary and long-term cultures of rat
GEC. GEC were sensitized with the complement-fixing 71
subclass of sheep anti-Fx1A IgG and exposed to various sera
serving as sources of complement [62]. Incubation of antibody-
sensitized GEC in normal human serum resulted in a sigmoidal
relationship between cytolysis and complement dose, consis-
tent with the 'multi-hit" requirement for cytolysis observed
with other nucleated cell types [25]. Cytolysis only occurred
when both anti-Fx1A and normal serum were present and not if
nonimmune IgG or C8-deficient plasma were substituted; re-
constitution of C8-deficient plasma with purified rat C8 restored
cytolysis however. Therefore, the nephritogenic antibody of
PHN directs insertion of the MAC into the GEC plasma
membrane, resulting in cytotoxicity. Noncytolytic ("sublytic")
injury was assessed using antibody-sensitized GEC that were
preloaded with biscarboxyethyl carboxyfluorescein (BCECF;
molecular wt —520 daltons), a low molecular weight molecule
that is largely retained by nonpermeabilized cells [62]. When
sensitized cells were subsequently incubated with a series of
limiting doses of complement, there was greater BCECF re-
lease than release of lactate dehydrogenase (molecular wt
140,000 daltons, a marker of cell death) at all serum concentra-
tions (Fig. 2A), thus demonstrating cell membrane perturbation
in the absence of cell death. Transmission electron microscopy
of cultured rat GEC that were incubated with sublytic amounts
of C5b-9 showed vesiculation of the apical and basolateral
plasma membranes, and shedding of membrane vesicles (Fig.
2B, 2C) [62, 63]. C5b-9 neoantigens were localized by immuno-
histological techniques to the plasma membranes, and were
shed in membrane vesicles (Fig. 2D) [63]. In addition, GEC that
were sublytically injured by C5b-9 demonstrated loss of desmo-
somal junctions, suggesting that C5b-9 may have affected the
intermediate filament structure (Fig. 2C) [62]. It should be noted
that many of these ultrastructural findings in cultured rat GEC
that were sublytically injured by the MAC are similar to the
GEC ultrastructure in PHN in the perfused kidney model
(discussed above).
Sublytic doses of complement, in addition to altering cell
membrane integrity and morphology in nucleated cells, can
stimulate phospholipid turnover with release of arachidonic
acid and production of eicosanoids [64]. In studies using GEC
outgrowths from explanted glomeruli, Hänsch et a! [26] showed
that C5b-9 stimulated a dose-dependent release of prostaglandin
E and thromboxane B2 within 5 to 10 minutes. Prostanoid
release was stimulated less effectively by C5b-8, and not at all
by C5b6. Prostaglandin E production was inhibited by both
cyclooxygenase and phospholipase inhibitors. These findings
are consistent with a complement-mediated increase in mem-
brane phospholipid turnover and are consistent with the obser-
vations of stimulated gbomerular prostanoid production in PHN
(discussed above). However, the results require confirmation in
a homogenous culture of GEC because the cell culture system
employed does not exclude the possibility that the prostanoids
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Fig. 2. Complement-mediated sublytic cytotoxicity of glomerular epithelial cells (GEC) in culture. (a) GEC on a collagen matrix were loaded with
biscarboxyethyl carboxyfluorescein (BCECF; molecular wt —520 daltons), incubated with anti-Fx1A IgG (I mg/mi, 22°C, 30 mm) and then various
concentrations of rat serum as a source of complement (37°C, 40 mm). Release of BCECF (LI), an indicator of cell membrane damage, is greater
at all serum concentrations than release of lactate dehydrogenase (LDH, •), an index of cell death. (b) Transmission electron micrograph of
antibody-sensitized GEC exposed to buffer alone. Cells appear normal with apical microvilli (arrowhead), tight junctions (long straight arrow), and
desmosomes (wavy arrows) (x 5400), (c) Transmission electron micrograph of antibody-sensitized GEC exposed to sublytic concentrations of rat
serum (7.5%). Microvilli (arrowheads) and tight junctions (long straight arrow) are present as in controls, however desmosomes are absent. In
addition, numerous vesicular structures are seen both on the apical surface and between cells (short arrows) (x 5400). (d) Immunoelectron
microscopy of the MAC on GEC in culture. GEC were exposed to anti-brush border vesicle IgG (50 sg/ml) and rat serum (15% vol/vol) for 15 mm
at 37°C. The medium was changed and the incubation continued for 30 mm. The cells were then fixed, and stained for rat C9 with colloidal
gold-labelled antisera. C9 is associated with membrane shed from the cell and to membranes remaining attached to the cell surface (x 25,000). (Fig.
2D reprinted from reference 66 with permission.)
might be derived from complement-stimulated mesangial cells
[65] within adherent glomeruli. Using homogeneous cultures of
rat GEC, Cybulsky et a! [66] recently demonstrated that C5b-9
rapidly increased cellular concentrations of 1,2-diacyiglycerol
and inositol trisphosphate, consistent with the activation of
phospholipase C. This was associated with an increase in the
intracellular free Ca2 concentration due to release of Ca2
from intracellular nonmitochondrial storage sites, as well as
Ca2 influx into cells. In addition, free arachidonic acid was
elevated, suggesting that activation of phospholipase A2 had
occurred. These observations also suggest that CSb-9 might
stimulate synthesis of eicosanoids in GEC. The pathways of
arachidonic acid release and eicosanoid synthesis in GEC
remain to be fully elucidated.
Thus, cell culture experiments have confirmed that GEC can
be a target for sublytic complement-mediated injury, and are
beginning to provide information on the alterations in cell
function induced by such injury. Further studies are necessary
to determine if CSb-9-induced phospholipase activation, eleva-
tion in intracellular free Ca2 concentration, and release of
eicosanoids lead to altered GEC morphology and impaired
glomerular permselectivity in PHN.
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